Abbott Gains CE Marks For New Tricuspid Device And Expanded Xience DES Indication
The next-generation TriClip G4 comes in more sizes than the original TriClip and features enhanced leaflet grasping features.
You may also be interested in...
September has been full of cardiovascular technology news, including announcements from Biotronik and Biosense Webster. Here are a few of the highlights.
Abbott expects the ongoing recovery of medical procedure volumes to continue even as new virus variants are causing COVID-19 cases to increase in some geographies.
The agency approved the Xience stents as suitable for patients at high bleeding-risk who can only stay on antiplatelet therapy for four weeks. Abbott also announced that it has received FDA approval and European CE mark approval for its Xience Skypoint stent.